BRPI0712273A2 - Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit - Google Patents

Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit Download PDF

Info

Publication number
BRPI0712273A2
BRPI0712273A2 BRPI0712273-0A BRPI0712273A BRPI0712273A2 BR PI0712273 A2 BRPI0712273 A2 BR PI0712273A2 BR PI0712273 A BRPI0712273 A BR PI0712273A BR PI0712273 A2 BRPI0712273 A2 BR PI0712273A2
Authority
BR
Brazil
Prior art keywords
antibody
methods
diagnose
kit
protein
Prior art date
Application number
BRPI0712273-0A
Other languages
English (en)
Inventor
K. Kirchhofer Daniel
Vij Rajesh
Original Assignee
Genentch, Inc., Empresa Americana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentch, Inc., Empresa Americana filed Critical Genentch, Inc., Empresa Americana
Publication of BRPI0712273A2 publication Critical patent/BRPI0712273A2/pt
Publication of BRPI0712273A8 publication Critical patent/BRPI0712273A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPOS ISOLADOS, POLIPEPTÍDEOS IMUNOGLOBULINAS, ANTICORPO HEPSINA, MOLÉCULA DE ÁCIDO NUCLEICO, CÉLULA HOSPEDEIRA, LINHAGEM CELULAR, MÉTODOS PARA PRODUZIR O ANTICORPO, PARA DIAGNOSTICAR A PRESENÇA DE HEPSINA, TRATAR UMA DOENÇA, PARA MONITORAR A DOENÇA RESIDUAL, PARA DETECTAR O ESTADO DA DOENÇA, PARA DIAGNOSTICAR UMA DISFUNÇçO, COMPOSIÇçO, ARRANJO OU CHIP DE PROTEÍNA E KIT <UM>RESUMO<MV> São fornecidos anticorpos monoclonais anti-HEPSINA e métodos para uso dos mesmos.
BRPI0712273A 2006-06-22 2007-06-20 anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit BRPI0712273A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80558906P 2006-06-22 2006-06-22
US60/805,589 2006-06-22
PCT/US2007/071688 WO2007149932A2 (en) 2006-06-22 2007-06-20 Methods and compositions for targeting hepsin

Publications (2)

Publication Number Publication Date
BRPI0712273A2 true BRPI0712273A2 (pt) 2012-03-06
BRPI0712273A8 BRPI0712273A8 (pt) 2019-01-22

Family

ID=38754528

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712273A BRPI0712273A8 (pt) 2006-06-22 2007-06-20 anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit

Country Status (16)

Country Link
US (2) US8124352B2 (pt)
EP (1) EP2044124A2 (pt)
JP (1) JP2009540835A (pt)
KR (1) KR101410195B1 (pt)
CN (1) CN101490088B (pt)
AU (1) AU2007260950B2 (pt)
BR (1) BRPI0712273A8 (pt)
CA (1) CA2656168A1 (pt)
IL (1) IL195561A (pt)
MX (1) MX2008015882A (pt)
MY (1) MY150643A (pt)
NO (1) NO20090333L (pt)
NZ (1) NZ573178A (pt)
RU (1) RU2009101813A (pt)
WO (1) WO2007149932A2 (pt)
ZA (1) ZA200810225B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316169B2 (en) 2004-12-13 2011-11-17 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
CN101490088B (zh) 2006-06-22 2015-04-08 健泰科生物技术公司 用于靶向hepsin的方法和组合物
EP2491059B1 (en) * 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
RU2539772C2 (ru) * 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011109308A1 (en) * 2010-03-02 2011-09-09 Seattle Genetics, Inc. Methods for screening antibodies
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
EP2714737A1 (en) * 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
WO2017162659A1 (en) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Intracellular hepsin as therapeutic target for the treatment of cancer with centrosome amplification

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268165B1 (en) 1997-03-19 2001-07-31 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US7282198B2 (en) 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
AU2001233262A1 (en) 2000-02-03 2001-08-14 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6423543B1 (en) 2000-12-20 2002-07-23 Isis Pharmaceuticals, Inc. Antisense modulation of hepsin expression
WO2002059373A2 (en) 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
CA2438433A1 (en) 2001-02-14 2002-08-22 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
US6482630B2 (en) 2001-03-29 2002-11-19 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030113762A1 (en) * 2001-08-17 2003-06-19 Warrington Janet A. Gleason grade 4/5 prostate cancer genes
WO2003064620A2 (en) 2002-01-31 2003-08-07 Irm, Llc Hepsin substrates and prodrugs
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
JP3775346B2 (ja) * 2002-05-29 2006-05-17 株式会社日立製作所 テレビ電話システムおよびその端末装置
WO2004009803A2 (en) 2002-07-23 2004-01-29 Bayer Healthcare Ag Regulation of human hepsin
US6977170B2 (en) 2002-09-06 2005-12-20 Applera Corporation Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
JP2006507813A (ja) * 2002-10-04 2006-03-09 シエーリング アクチエンゲゼルシャフト 置換体活性化配列を有する修飾されたヘプシン分子及びその使用
KR101222254B1 (ko) 2004-07-26 2013-01-16 제넨테크, 인크. 간세포 성장 인자 활성화를 조정하기 위한 조성물 및 방법
CN101490088B (zh) 2006-06-22 2015-04-08 健泰科生物技术公司 用于靶向hepsin的方法和组合物
US20100061996A1 (en) * 2006-06-22 2010-03-11 Genentech, Inc. Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
EP2491059B1 (en) * 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same

Also Published As

Publication number Publication date
NZ573178A (en) 2012-02-24
ZA200810225B (en) 2010-03-31
CA2656168A1 (en) 2007-12-27
NO20090333L (no) 2009-03-23
US8383123B2 (en) 2013-02-26
MY150643A (en) 2014-02-14
EP2044124A2 (en) 2009-04-08
IL195561A (en) 2013-04-30
BRPI0712273A8 (pt) 2019-01-22
US20100021474A1 (en) 2010-01-28
WO2007149932A3 (en) 2008-05-02
IL195561A0 (en) 2011-08-01
AU2007260950B2 (en) 2011-09-15
CN101490088A (zh) 2009-07-22
RU2009101813A (ru) 2010-07-27
CN101490088B (zh) 2015-04-08
WO2007149932A2 (en) 2007-12-27
MX2008015882A (es) 2009-01-12
KR101410195B1 (ko) 2014-06-19
US20120141374A1 (en) 2012-06-07
KR20090029276A (ko) 2009-03-20
AU2007260950A1 (en) 2007-12-27
JP2009540835A (ja) 2009-11-26
AU2007260950A8 (en) 2009-01-22
US8124352B2 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
BRPI0712273A8 (pt) anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
BR112012007365A2 (pt) proteínas de ligação à il-1
BRPI0519775A2 (pt) proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica
WO2010009987A3 (en) Diagnostic antibody assay
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BR112015014751A2 (pt) anticorpos anti-tau humanos
ATE443161T1 (de) Mittel und verfahren für den nachweis von methylierter dna
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
EP2826791A3 (en) Humanized anti-C5aR antibodies
KR102311590B1 (ko) 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물
JP2013116897A5 (pt)
IL212056A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
ATE474857T1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
WO2017027685A3 (en) Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
WO2007111875A3 (en) Methods for diagnosing and treating kidney and colorectal cancer
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
EP2083018A3 (en) Compositions and methods relating to STOP-1
ES2226823T3 (es) Isoforma c de la tenascina como marcador de neoplasias.
WO2004058986A3 (en) Btl-ii nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]